Literature DB >> 32272980

Autoimmune bullous skin diseases, pemphigus and pemphigoid.

Shohei Egami1, Jun Yamagami2, Masayuki Amagai3.   

Abstract

Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Based on these advances, several new therapeutic approaches have become available, and more effective and less toxic targeted approaches are under development.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune bullous diseases; BP180; ELISA; desmoglein; rituximab; type XVII collagen BP230

Year:  2020        PMID: 32272980     DOI: 10.1016/j.jaci.2020.02.013

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

Review 1.  Serological Biomarkers and Their Detection in Autoimmune Bullous Skin Diseases.

Authors:  Ilana Heckler; Michael Hong; Animesh Amart Sinha; Iswariya Venkataraman
Journal:  Dermatol Pract Concept       Date:  2022-04-01

Review 2.  Milestones in Personalized Medicine in Pemphigus and Pemphigoid.

Authors:  Katja Bieber; Khalaf Kridin; Shirin Emtenani; Katharina Boch; Enno Schmidt; Ralf J Ludwig
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561

3.  Analysis of the autoimmune response against BP180 in patients with Alzheimer's disease.

Authors:  Ya-Nan Wang; Christoph M Hammers; Xuming Mao; Hong-Zhong Jin; Jing Yuan; Li Li
Journal:  Ann Transl Med       Date:  2021-01

Review 4.  Skin-Associated B Cells in the Pathogenesis of Cutaneous Autoimmune Diseases-Implications for Therapeutic Approaches.

Authors:  Tanja Fetter; Dennis Niebel; Christine Braegelmann; Joerg Wenzel
Journal:  Cells       Date:  2020-12-07       Impact factor: 6.600

5.  Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers.

Authors:  Christian D Sadik; Ewan A Langan; Ralf Gutzmer; Maria Isabel Fleischer; Carmen Loquai; Lydia Reinhardt; Friedegund Meier; Daniela Göppner; Rudolf A Herbst; Detlef Zillikens; Patrick Terheyden
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Case Report: Variety of Target Antigens During 1 Year Follow-Up of a Patient Initially Diagnosed With Bullous Pemphigoid.

Authors:  Hua Qian; Zhijun Zhou; Luhuai Shi; Huicheng Li; Weijun Liu; Yong Ai; Yangmin Gao; Suying Feng; Takashi Hashimoto; Xiaoguang Li
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 7.  Role of the CXCL13/CXCR5 Axis in Autoimmune Diseases.

Authors:  Zijian Pan; Tong Zhu; Yanjun Liu; Nannan Zhang
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

8.  Up-regulation of ST18 in pemphigus vulgaris drives a self-amplifying p53-dependent pathomechanism resulting in decreased desmoglein 3 expression.

Authors:  Sari Assaf; Dan Vodo; Kiril Malovitski; Janan Mohamad; Shir Bergson; Yarden Feller; Liron Malki; Ofer Sarig; Eli Sprecher
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

Review 9.  Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.

Authors:  Elena Calabria; Federica Canfora; Massimo Mascolo; Silvia Varricchio; Michele Davide Mignogna; Daniela Adamo
Journal:  Pathol Res Pract       Date:  2022-03-05       Impact factor: 3.309

10.  Autoantibodies against desmoglein 2 are not pathogenic in pemphigus.

Authors:  Marcela Calixto Brandão Miguel; Tamiris Amanda Julio; Sebastian Vernal; Natália Aparecida de Paula; Andre Lieber; Ana Maria Roselino
Journal:  An Bras Dermatol       Date:  2022-01-17       Impact factor: 2.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.